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INTRODUCTION
This chapter makes treatment recommendations for MPGN
believed to be of unknown cause (idiopathic MPGN)
in adults and children. The cost implications for global
application of this guideline are addressed in Chapter 2.
8.1: Evaluation of MPGN
8.1.1: Evaluate patients with the histological (light-
microscopic) pattern of MPGN for under-
lying diseases before considering a specific
treatment regimen (see Table 20). (Not
Graded)
BACKGROUND
MPGN is a light-microscopic ‘‘pattern of injury’’ caused by
many disorders (see Table 20).304,305 Patients commonly
present with nephrotic syndrome, hypertension, glomerular
hematuria, and progressive kidney dysfunction.304,305 Reduc-
tion in the serum concentration of complement compo-
nents (C3 and/or C4) is commonly, but not uniformly,
observed.305,306
MPGN can be further classified based on the extent and
location of deposits of immunoglobulin and/or complement.
The classification of MPGN according to ultrastructural
appearances into MPGN type I, II, or III is commonly
employed, but newer classification schema based on im-
munopathology are replacing this approach.307,308 Type I
MPGN is associated with subendothelial and mesangial
electron-dense deposits containing immunoglobulin and/or
C3,305,309,310 and is often due to an underlying chronic
hepatitis B or C infection (see Chapter 9); type II MPGN
with electron dense intramembranous deposits containing
numerous complement components, but not immunoglo-
bulin305,309 and is now known as ‘‘dense-deposit disease’’. It
has a distinctive etiology based on inherited or acquired
abnormalities of complement regulatory proteins.305,311
Other rarer variants (type III MPGN) are also recognized
based on abnormalities of the glomerular basement mem-
brane and the location of electron-dense deposits. Immuno-
pathological variants are recognized based on deposition of
IgG and/or C3 component of complement in glomeruli.
Those in which C3 is exclusively deposited are known as
C3 GN.305,307,308,311
Treatment of MPGN is highly dependent on proper
identification of underlying causes (see Table 20). In some
patients C3 nephritic factor, an autoantibody to C3bBb,
can be involved in the pathogenesis of type I, II, III, or
C3 GN.312,313
Idiopathic MPGN is defined by exclusion of any other
identifiable cause, most typically when the ultrastructural
pattern is type I MPGN. Idiopathic type I MPGN is very
uncommon in developed countries, but remains a relatively
common, although diminishing, cause of nephrotic syn-
drome in developing countries, especially those with a high
burden of endemic infectious diseases.314
RATIONALE
K Based on the heterogeneity of cause and pattern of
histologic injury of MPGN, all patients with MPGN must
be thoroughly evaluated for underlying diseases before
being classified as idiopathic MPGN, and before any
specific treatment decisions can be made.
8.2: Treatment of idiopathic MPGN
8.2.1: We suggest that adults or children with
presumed idiopathic MPGN accompanied by
nephrotic syndrome AND progressive decline
of kidney function receive oral cyclophos-
phamide or MMF plus low-dose alternate-day
or daily corticosteroids with initial therapy
limited to less than 6 months. (2D)
RATIONALE
K There is very low–quality evidence to suggest the benefit of
an immunosuppressive agent plus corticosteroids in the
treatment of idiopathic (type I) MPGN with nephrotic
syndrome and/or deteriorating kidney function.
MPGN is identified by exclusion of all other known causes
of the MPGN pattern on kidney biopsy. When there is a
secondary MPGN, i.e., a defined cause for the MPGN pattern
(see Table 20), treatment should be directed against that
cause. A review of the evidence for the management of each
of those conditions enumerated in Table 20 is outside the
scope of this guideline. This section will consider only those
patients who do not have any recognized underlying cause or
pathobiological mechanism for the MPGN lesion. Most of
these patients will have the type I pattern by electron
microscopy.
Many of the early reports of treatment of ‘‘idiopathic’’
MPGN likely inadvertently included cases of secondary
MPGN. Therefore, the results of these studies must now be
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interpreted with great caution given today’s knowledge
regarding immunopathogenesis.304,305,307,308 Truly ‘‘idio-
pathic’’ MPGN is now a very uncommon condition, except
in certain developing countries with a high endemic burden
of infections. The few RCTs of treatment of idiopathic MPGN
in children and adults have given inconsistent and largely
inconclusive results.304,305 Many of the reported trials have
weak experimental design or are underpowered, and thus the
evidence base underlying the recommendations for treatment
of ‘‘idiopathic’’ MPGN is very weak. Early claims of benefit
for a combination of aspirin and dipyridamole for adults
with idiopathic MPGN were later rejected315,316 and benefits
of ‘‘antiplatelet’’ therapy in ‘‘idiopathic’’ MPGN remain in
doubt.317,318
The benefit of long-term alternate-day corticosteroid
therapy for ‘‘idiopathic’’ MPGN in children was suggested
by observational studies and a single RCT, but the results
were equivocal; there have been no subsequent confirmatory
RCTs.319–322
The benefits of immunosuppressive therapy (cyclophos-
phamide or MMF) often combined with high-dose i.v. or
oral steroids have never been demonstrated in RCTs.
However, small, observational studies with short-term
follow-up have suggested a benefit, mostly in subjects with
a rapidly progressive course, often associated with extensive
crescents, or in those with progressive kidney disease with
persistence of severe nephrotic syndrome.145,317,323–329 Pub-
lication bias might be operative in these reports. Progressive
renal failure remains the only indication for immuno-
suppressive treatment, but the overall evidence for efficacy
and safety is weak. See Chapters 13 and 14 for discussion of
treatment of those cases of MPGN with superimposed
extensive crescentic lesions and rapidly progressive renal
failure.
RESEARCH RECOMMENDATION
K An RCT is needed to test corticosteroids in combination
with an immunosuppressive agent such as cyclophos-
phamide, MMF, or rituximab in ‘‘idiopathic’’ MPGN
with nephrotic syndrome in adults and children.
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Table 20 | Underlying conditions associated with a
membranoproliferative pattern of GN
Chronic infections (especially hepatitis C)
Autoimmune diseases (especially LN)
Monoclonal gammopathies (especially light-chain deposition disease and
monoclonal IgG disease)
Complement dysregulation (especially complement factor H deficiency)
Chronic and healed thrombotic microangiopathies
GN, glomerulonephritis; LN, lupus nephritis.
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